The ability of glucocorticoids (GCs) to kill lymphoid cells via a process called apoptosis has led to their inclusion in essentially all chemotherapy protocols for lymphoid malignancies. Since GC receptor(GR) is a ligand-dependent transcription factor, there should be genes mediating apoptosis among the ones whose expression is induced by GC. This review summarizes recent advances related to the molecular basis of GC-induced apoptosis, focusing on microarray analysis. Various groups of genes have been identified as candidate target genes of GR including the ones encoding Bcl-2 family proteins and calcineurin inhibitors. Although further investigation is required to determine the genes causally involved in GC-induced apoptosis, the studies described here will hopefully lead to more efficient treatments of lymphoid malignancies.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A case report of Castleman disease with paraneoplastic pemphigus and bronchiolitis obliterans: Challenges and key takeaways.
Int J Surg Case Rep
January 2025
Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Center, Pakistan; Shaukat Khanum Memorial Cancer Hospital and Research Centre, 7A Block R-3, M.A.Johar Town, Lahore, Pakistan. Electronic address:
Introduction: Castleman disease is a rare lymphoproliferative disorder, subdivided into three types: unicentric Castleman disease, idiopathic multicentric Castleman disease and human herpesvirus-8 (HHV8) associated multicentric Castleman disease. The retroperitoneum comprises only 13 % of the cases.
Case Presentation: We report a case of a 36-year-old female who presented with skin lesions in a dermatology clinic.
Alarmin' lymphoid developments.
Sci Signal
January 2025
Science Signaling, AAAS, Washington, DC 20005, USA.
The alarmin cytokine IL-33 stimulates the formation of immune hubs within otherwise "cold" tumors.
View Article and Find Full Text PDFComparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma.
J Immunother Cancer
January 2025
Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
Background: Cholangiocarcinoma is a challenging malignancy with limited responses to conventional therapies, particularly immune checkpoint inhibitor therapy. Tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLSs) are key components of the tumor microenvironment (TME) and have been implicated in the immune response to cancer. However, the role and difference of TLSs and TILs in patients with cholangiocarcinoma remains unclear.
View Article and Find Full Text PDFT-cell prolymphocytic leukemia (T-PLL) is an aggressive lymphoid malignancy with limited treatment options. To discover new treatment targets for T-PLL, we performed high-throughput drug sensitivity screening on 30 primary patient samples ex-vivo. After screening over 2'800 unique compounds, we found T-PLL to be more resistant to most drug classes, including chemotherapeutics, compared to other blood cancers.
View Article and Find Full Text PDFCutaneous involvement in multiple myeloma is rare and may present as nodules mimicking other lymphoid neoplasms. It typically occurs late in the course of the disease and is associated with an aggressive clinical course and poor prognosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!